News

In his May letter, Christopher Bunick, MD, PhD, reflects on his journey as a physician-scientist and advocates for supporting foundations dedicated to rare skin diseases.

Catch up on dermatology news, highlights, and insights from the past 24 hours.

This Melanoma Monday, we take a look at melanoma care in the US, from treatments to persistent gaps in access, early detection, and long-term outcomes.

Researchers conducted a review of adherence behaviors for patients with dermatological diseases and provided an update on management strategies.

Explore vital insights on melanoma awareness, skin cancer disparities, and atopic dermatitis management in the latest issue of Dermatology Times.

Ixekizumab shows promise in restoring clinical response for hidradenitis suppurativa patients previously unresponsive to adalimumab, highlighting new treatment options.

Peter Lio, MD, discusses innovative treatments for pediatric atopic dermatitis, including microbiome therapies and botanical options.

Christopher Bunick, MD, PhD, discusses the evolving role of OX40-targeted biologics in atopic dermatitis treatment ahead of the upcoming RAD conference.

Explore the top headlines of the week including insights on the latest clinical trials, therapeutic updates, and more.

Test your knowledge of key words and terms associated with dermatology news from the previous week.

In case you missed it, this week we had news about the first FDA-approved gene therapy for RDEB, the influence of psoriasis on sun tanning addiction, and resources for Rosacea Awareness Month.

This week, we feature top articles from our sister publications on regulatory updates, clinical trial insights, and more.

Put your dermatology expertise to the test with Dermatology Times’ interactive quiz series!

Catch up on dermatology news, highlights, and insights from the past 24 hours.

Patients with mucous membrane pemphigoid face increased skin cancer risks, particularly squamous cell carcinoma, highlighting the need for vigilant screening.

A novel electrotrichogenic device shows promising results in promoting dense, thickened hair growth for male androgenetic alopecia patients.

Collagen structure and vessel density vary by photoaging type, highlighting the value of multimodal imaging in guiding individualized skin care strategies.

Guselkumab shows high effectiveness and safety in treating moderate to severe plaque psoriasis, enhancing quality of life in real-world Korean patients.

Stage IV melanoma survivors face persistent adverse effects and distress, highlighting the need for targeted psychological support and care.

New findings reveal DecisionDx-Melanoma more accurately identifies patients with under 5% risk of SLN positivity, supporting safer avoidance of SLNB surgery.

Catch up on dermatology news, highlights, and insights from the past 24 hours.

Explore the urgent need for sustainability in dermatology, addressing its environmental impact and advocating for eco-friendly practices in health care.

A study reveals that combining botulinum toxin A and hyaluronic acid significantly reduces acne-related enlarged pores, enhancing skin texture and patient satisfaction.

The social media campaign aims to educate, inspire prevention, and support actinic keratosis awareness leading up to Global AK Awareness Day on May 24.

The Photobiology Committee also issues a public safety warning regarding sun protection misinformation amid growing rates of skin cancer in the U.S.

A new study reveals the effectiveness of two isotretinoin doses for treating recalcitrant facial flat warts, enhancing quality of life and reducing anxiety.

Acoustic stimulation using infrasound and low-frequency sound enhances wound healing, promoting cellular activity and tissue repair in innovative, non-invasive ways.

Dermatology Times has compiled a list of dermatological meetings taking place during the month of May.

Catch up on dermatology news, highlights, and insights from the past 24 hours.

Raj Chovatiya, MD, PhD, MSCI, reviews the limitations of chronic steroid use and highlights available topicals, including ruxolitinib, roflumilast, and tapinarof.